Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Collegium Pharmaceutical ( (COLL) ) has provided an announcement.
On May 15, 2025, Collegium Pharmaceutical held its Annual Meeting of Shareholders, where the 2025 Equity Incentive Plan was approved, allowing stock-based awards for company personnel. Additionally, shareholders elected eight directors, approved executive compensation, set the frequency of advisory votes on compensation to annually, and ratified Deloitte & Touche LLP as the independent accounting firm for 2025.
The most recent analyst rating on (COLL) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.
Spark’s Take on COLL Stock
According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.
Collegium Pharmaceutical shows strong financial performance and strategic growth prospects, notably in the ADHD segment with Jornay PM. While high leverage and increased operating expenses pose risks, effective cash management and strategic initiatives provide confidence. Technical indicators suggest a cautious bullish trend, and the stock’s valuation is reasonable, supporting its potential for future growth.
To see Spark’s full report on COLL stock, click here.
More about Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines for pain management. The company primarily offers products designed to address the misuse and abuse of prescription medications, with a market focus on providing effective pain management solutions.
Average Trading Volume: 410,954
Technical Sentiment Signal: Hold
Current Market Cap: $971.7M
Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.